Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicineFDA granted provisional determination for interchangeability designation for Pyzchiva®Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US Basel,
Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener